<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - HALOPERIDOL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>HALOPERIDOL</h1>

        <p><a href="../drugClass/PHP34569.html">ANTIPSYCHOTIC DRUGS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Nausea and vomiting in palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1.5 mg 1&#8211;2 times a day, increased if necessary to 5&#8211;10 mg daily in divided doses.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                5&#8211;15 mg, to be administered over 24 hours.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                1&#8211;2 mg.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                2.5&#8211;10 mg/24 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Schizophrenia</span>,
                <span class="indication">Psychoses</span>,
                <span class="indication">Mania and hypomania</span>,
                <span class="indication">Organic brain damage (depending on symptoms)</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2&#8211;20 mg once daily, alternatively initially 2&#8211;20 mg daily in divided doses; maintenance 1&#8211;3 mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses, for debilitated patients, use elderly dose; maximum 20 mg per day.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 1&#8211;10 mg once daily, alternatively initially 1&#8211;10 mg daily in divided doses; maintenance 1&#8211;3 mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses; maximum 20 mg per day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2&#8211;5 mg, repeated if necessary, repeated dose given according to response and tolerability, for debilitated patients, use elderly dose; maximum 12 mg per day.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 1&#8211;2.5 mg, repeated if necessary, repeated dose given according to response and tolerability; maximum 12 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Agitation and restlessness in the elderly</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 0.75&#8211;1.5 mg 2&#8211;3 times a day, adjusted according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Management of mental or behavioural problems such as aggression, hyperactivity and self-mutilation in the mentally retarded and in patients with organic brain damage (depending on symptoms)</span>,
                <span class="indication">Gilles de la Tourette syndrome</span>,
                <span class="indication">Severe tics</span>,
                <span class="indication">Intractable hiccup</span>,
                <span class="indication">Adjunct to short-term management of moderate to severe psychomotor agitation, excitement and, violent or dangerously impulsive behaviour</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1.5&#8211;3 mg 2&#8211;3 times a day, alternatively initially 3&#8211;5 mg 2&#8211;3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5&#8211;1 mg 3 times a day, increased if necessary to 2&#8211;3 mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose, for debilitated patients, use elderly dose.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 0.75&#8211;1.5 mg 2&#8211;3 times a day, alternatively initially 1.5&#8211;2.5 mg 2&#8211;3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5&#8211;1 mg 3 times a day, increased if necessary to 2&#8211;3 mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Restlessness and confusion in palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2 mg, then 2 mg every 2 hours if required.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                2.5 mg, then 2.5 mg every 2 hours if required.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                5&#8211;15 mg standard 24 hours.</li>
            </ul>
          </section>
        </section>
        
            <section class="doseAdjustments">
                <h3>Dose adjustments due to interactions</h3>
              <p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>
            </section>
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid unless benefits outweigh risks.</p><p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Can precipitate coma.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Bradycardia</li>
            <li>CNS depression</li>
            <li>comatose states</li>
            <li>lesions of the basal ganglia</li>
            <li>Parkinson's disease</li>
            <li>phaeochromocytoma</li>
            <li>QT-interval prolongation</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Depression, weight loss,
              </p>
              <p>
                <strong>uncommon:</strong> Dyspnoea, oedema,
              </p>
              <p>
                <strong>rare:</strong> Bronchospasm, hypoglycaemia, inappropriate antidiuretic hormone secretion, photosensitivity reactions, pigmentation,
              </p>
              <p>
                <strong>notKnown:</strong> Hypertension, Stevens-Johnson syndrome, sweating, toxic epidermal necrolysis,
              </p>
        
        
            <section class="advice">
              <p>Less sedating and fewer antimuscarinic or hypotensive symptoms.</p>
            </section>
        
      </section>




      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <p>When prescribing, dispensing or administering, check that this injection is the correct preparation&#8212;this preparation is usually used in hospital for the rapid control of an <i>acute episode</i> and should <b>not</b> be confused with depot preparations which are usually used in the community or clinics for <i>maintenance</i> treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Arteriosclerosis
          </li>
          <li>
            hypocalcaemia
          </li>
          <li>
            hypokalaemia
          </li>
          <li>
            hypomagnesaemia
          </li>
          <li>
            metabolic disturbances
          </li>
          <li>
            subarachnoid haemorrhage
          </li>
          <li>
            thyrotoxicosis
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Baseline ECG required before treatment&#8212;assess need for further ECGs during treatment on an individual basis.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>BNF doses for schizophrenia, psychoses, mania, hypomania, and organic brain damage differ from those in product literature.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of HALOPERIDOL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,

            <div id="PHP74919"><a href="../medicinalForm/PHP74919.html" data-target="#PHP74919" data-action="load">Tablet</a></div>
            <div id="PHP74925"><a href="../medicinalForm/PHP74925.html" data-target="#PHP74925" data-action="load">Capsule</a></div>
            <div id="PHP74951"><a href="../medicinalForm/PHP74951.html" data-target="#PHP74951" data-action="load">Oral solution</a></div>
            <div id="PHP74933"><a href="../medicinalForm/PHP74933.html" data-target="#PHP74933" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
